

CSD/BSE&NSE/2025-26 December 2, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Scrip Code: 543064

To

The Manager
Listing Department
National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai – 400 051

Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: <u>Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)</u> Regulations, 2015 regarding fund infusion in NJ Bio Inc.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we hereby inform that the Board of Directors of the Company at its meeting held today, i.e. on December 2, 2025 has approved the fund infusion by way of investment in Compulsorily Convertible Preferred Stock of NJ Bio Inc, USA, a subsidiary of the Company, upto an amount of USD 10 million. The fund when deployed will be used by the said subsidiary to support its growth initiatives including capex.

The details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, will be disclosed to the stock exchange(s) after approval of the Board of the said subsidiary.

We request you to take this information on record.

Thanking you.

Yours faithfully, For **Cohance Lifesciences Limited** (Formerly, Suven Pharmaceuticals Limited)

Kundan Kumar Jha

Company Secretary, Compliance Officer and Head-Legal



(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad - 500081, Telangana, India. Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India. Tel: +91 22 6153 9999

